Deal Announcements

Trillium Therapeutics Receives Third VC Funding

Friday, September 19, 2008 6:04:00 AM PDT | VentureDeal Staff

Toronto, Ontario  -- Pharmaceutical company Trillium Therapeutics has garnered $12 million in its series C venture capital investment round.

Trillium is focused on the discovery and development of therapies that restore balance to the immune system after autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases.

BDC Venture Capital and the Canadian Medical Discoveries Fund were among the investors. The company said it would use the funding proceeds to advance its lead product candidate, TTI-1612, through clinical trials.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1